A randomized trial of topical cyclosporin 0.05% in topical steroid-resistant atopic keratoconjunctivitis

Ophthalmology

Volumn 111, Issue 3, 2004, Pages 476-482

  Akpek, Esen Karamursel ^a   Dart, John K ^b   Watson, Stephanie ^b   Christen, William ^c   Dursun, Dilek ^d   Yoo, Sonia ^d   O'Brien, Terrence P ^a   Schein, Oliver D ^a   Gottsch, John D ^a  

^a JOHNS HOPKINS UNIVERSITY   (United States)

^b MOORFIELDS EYE HOSPITAL   (United Kingdom)

^c BRIGHAM AND WOMEN S HOSPITAL   (United States)

^d UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOSPORIN; CYCLOSPORIN A; EYE DROPS; STEROID;

ADULT; AGED; ARTICLE; ATOPIC KERATOCONJUNCTIVITIS; BLEPHARITIS; CICATRIZING CONJUNCTIVITIS; CLINICAL ARTICLE; CLINICAL FEATURE; CLINICAL TRIAL; CONJUNCTIVAL HYPEREMIA; CONJUNCTIVITIS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORNEA NEOVASCULARIZATION; CORRELATION ANALYSIS; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; EYE DISEASE; FEMALE; HUMAN; INTERMETHOD COMPARISON; KERATOCONJUNCTIVITIS; MALE; MATHEMATICAL COMPUTING; MULTICENTER STUDY; OUTCOMES RESEARCH; PATIENT SELECTION; PHOTOPHOBIA; PRIORITY JOURNAL; PRURITUS; PUNCTATE KERATITIS; RANDOMIZED CONTROLLED TRIAL; SCORING SYSTEM; SIDE EFFECT; SYMPTOM; UPPER TARSAL CONJUNCTIVAL PAPILLA;

ADMINISTRATION, TOPICAL; ADULT; AGED; CONJUNCTIVITIS, ALLERGIC; CYCLOSPORINE; DOUBLE-BLIND METHOD; DRUG RESISTANCE; FEMALE; GLUCOCORTICOIDS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MALE; MIDDLE AGED; OPHTHALMIC SOLUTIONS; SAFETY;

EID: 1442348757     PISSN: 01616420     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ophtha.2003.05.035     Document Type: Article

References (25)

1. Foster C.S., Rice B.A., Dutt J.E. Immunopathology of atopic keratoconjunctivitis. Ophthalmology. 98:1991;1190-1196.
2. Metz D.P., Hingorani M., Calder V.L., et al. T-cell cytokines in chronic allergic eye disease. J Allergy Clin Immunol. 100:1997;817-824.
3. Foster C.S., Calonge M. Atopic keratoconjunctivitis. Ophthalmology. 97:1990;992-1000.
4. Power W.J., Tugal-Tutkun I., Foster C.S. Long-term follow-up of patients with atopic keratoconjunctivitis. Ophthalmology. 105:1998;637-642.
5. Nussenblatt R.B., Palestine A.G. Cyclosporine A immunology, pharmacology and therapeutic uses. Surv Ophthalmol. 31:1986;159-169.
6. Whitcup S.M., Chan C.C., Luyo D.A., et al. Topical cyclosporine inhibits mast cell-mediated conjunctivitis. Invest Ophthalmol Vis Sci. 37:1996;2686-2693.
7. Hingorani M., Moodaley L., Calder V.L., et al. A randomized, placebo-controlled trial of topical cyclosporin A in steroid-dependent atopic keratoconjunctivitis. Ophthalmology. 105:1998;1715-1720.
8. Hogan M.Y. Atopic keratoconjunctivitis. Trans Am Ophthalmol Soc. 50:1952;265-281.
9. Akpek E.K., Hasiripi H., Christen W.G., Kalayci D. A randomized trial of low-dose, topical mitomycin-C in the treatment of severe vernal keratoconjunctivitis. Ophthalmology. 107:2000;263-269.
10. Belfort R., Marbeck P., Hsu C.C., Freitas D. Epidemiological study of 134 subjects with allergic conjunctivitis. Acta Ophthalmol Scand Suppl. 230:2000;38-40.
11. Tuft S.J., Kemeny D.M., Dart J.K., Buckley R.J. Clinical features of atopic keratoconjunctivitis. Ophthalmology. 98:1991;150-158.
12. Faulds D., Goa K.L., Benfield P. Cyclosporin A a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in immunoregulatory disorders. Drugs. 45:1993;953-1040.
13. Hoang-Xuan T., Prisant O., Hannouche D., Robin H. Systemic cyclosporine A in severe atopic keratoconjunctivitis. Ophthalmology. 104:1997;1300-1305.
14. Hunter P.A., Wilhelmus K.R., Rice N.S., Jones B.R. Cyclosporin A applied topically to the recipient eye inhibits corneal graft rejection. Clin Exp Immunol. 45:1981;173-177.
15. Kana J.S., Hoffmann B., Buchen R., et al. Rabbit corneal allograft survival following topical administration of cyclosporin A. Invest Ophthalmol Vis Sci. 22:1982;686-690.
16. Behrens-Baumann W., Theuring S., Brewitt H. The effect of topical cyclosporin A on the rabbit cornea a clinical and electron microscopic study. Graefes Arch Clin Exp Ophthalmol. 224:1986;520-524.
17. Zierhut M., Thiel H.J., Weidle E.G., et al. Topical treatment of severe corneal ulcers with cyclosporin A. Graefes Arch Clin Exp Ophthalmol. 227:1989;30-35.
18. Holland E.J., Olsen T.W., Ketcham J.M., et al. Topical cyclosporin A in the treatment of anterior segment inflammatory disease. Cornea. 12:1993;413-419.
19. Kaan G., Ozden O. Therapeutic use of topical cyclosporine. Ann Ophthalmol. 25:1993;182-186.
20. Gunduz K., Ozdemir O. Topical cyclosporin as an adjunct to topical acyclovir treatment in herpetic stromal keratitis. Ophthalmic Res. 29:1997;405-408.
21. Gottsch J.D., Akpek E.K. Topical cyclosporin stimulates neovascularization in resolving sterile rheumatoid central corneal ulcers. Trans Am Ophthalmol Soc. 98:2000;81-87., discussion 87-90.
22. Del Castillo JM, Del Castillo JB, Garcia-Sanchez J. Effect of topical cyclosporin A on Thygeson's superficial punctate keratitis. Doc Ophthalmol 1996-97;93:193-8.
23. Bleik J.H., Tabbara K.F. Topical cyclosporine in vernal keratoconjunctivitis. Ophthalmology. 98:1991;1679-1684.
24. Mendicute J., Aranzasti C., Eder F., et al. Topical cyclosporin A 2% in the treatment of vernal keratoconjunctivitis. Eye. 11:(pt 1):1997;75-78.
25. Sall K., Stevenson O.D., Mundorf T.K., et al. Two multicenter, randomized studies of the efficacy and safety of cyclosporine ophthalmic emulsion in moderate to severe dry eye disease. Ophthalmology. 107:2000;631-639.